Immune-Related Adverse Events From Immune Checkpoint Inhibitors

K. A. Marrone, W. Ying, J. Naidoo

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


Immunotherapy for cancer treatment has come of age, specifically with the use of immune checkpoint antibodies directed against molecules such as CTLA-4, PD-1, and PD-L1. Single-agent and combinatorial approaches utilizing these agents and other immunotherapies that may enhance antitumor effects are under investigation. With increasing clinical use of these agents, an appreciation for their toxicities comes to the fore. Adverse events that occur as a result of the immunologic effects of these therapies are termed “immune-related adverse events” (irAEs), and range in both frequency and severity in reported single-agent and combination studies. Improvements in our understanding of how and why irAEs develop and how to effectively manage them are needed. Herein we provide a state-of-the-art synopsis of the incidence, clinical features, mechanisms, and management of selected irAEs with immune checkpoint inhibitors currently in use.

Original languageEnglish (US)
Pages (from-to)242-251
Number of pages10
JournalClinical pharmacology and therapeutics
Issue number3
StatePublished - Sep 2016

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Immune-Related Adverse Events From Immune Checkpoint Inhibitors'. Together they form a unique fingerprint.

Cite this